Sino Medical Sciences Technology In (688108) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sino Medical Sciences Technology In (688108) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥31.52 Million ≈ $4.61 Million USD) by net assets (CN¥931.81 Million ≈ $136.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sino Medical Sciences Technology In - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sino Medical Sciences Technology In's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sino Medical Sciences Technology In (688108) financial obligations for a breakdown of total debt and financial obligations.
Sino Medical Sciences Technology In Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sino Medical Sciences Technology In ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jupiter Wagons Limited
NSE:JWL
|
0.005x |
|
Kinpo Electronics Inc
TW:2312
|
-0.004x |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
0.014x |
|
Vulcan Energy Resources Ltd
AU:VUL
|
-0.049x |
|
Grupo Aeroméxico S.A.B. de C.V
MX:AEROMEX
|
-0.311x |
|
Afry AB
ST:AFRY
|
0.105x |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
0.057x |
|
Couchbase Inc
NASDAQ:BASE
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Sino Medical Sciences Technology In (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sino Medical Sciences Technology In from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 688108 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥898.34 Million ≈ $131.46 Million |
CN¥131.24 Million ≈ $19.20 Million |
0.146x | +121.46% |
| 2023-12-31 | CN¥861.65 Million ≈ $126.09 Million |
CN¥56.84 Million ≈ $8.32 Million |
0.066x | +152.59% |
| 2022-12-31 | CN¥887.48 Million ≈ $129.87 Million |
CN¥-111.31 Million ≈ $-16.29 Million |
-0.125x | -97.14% |
| 2021-12-31 | CN¥945.16 Million ≈ $138.31 Million |
CN¥-60.13 Million ≈ $-8.80 Million |
-0.064x | -197.25% |
| 2020-12-31 | CN¥1.08 Billion ≈ $157.73 Million |
CN¥70.51 Million ≈ $10.32 Million |
0.065x | -47.78% |
| 2019-12-31 | CN¥1.10 Billion ≈ $160.75 Million |
CN¥137.61 Million ≈ $20.14 Million |
0.125x | -9.96% |
| 2018-12-31 | CN¥701.28 Million ≈ $102.62 Million |
CN¥97.56 Million ≈ $14.28 Million |
0.139x | +20.02% |
| 2017-12-31 | CN¥606.70 Million ≈ $88.78 Million |
CN¥70.32 Million ≈ $10.29 Million |
0.116x | -44.37% |
| 2016-12-31 | CN¥202.75 Million ≈ $29.67 Million |
CN¥42.24 Million ≈ $6.18 Million |
0.208x | -- |
About Sino Medical Sciences Technology In
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China. Its products include coronary drug stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents. The company was founded in 2007 and is headquartered in Tianjin, China.